Clinical Edge Journal Scan

MIC of PASDAS could serve as an additional tool to understand patients’ perspectives of PsA


 

Key clinical point: Minimal important change (MIC) of the Psoriatic Arthritis Disease Activity Score (PASDAS) could help physicians understand patients' perspectives of disease activity and provide an additional tool for the treatment of psoriatic arthritis (PsA).

Major finding: The overall MIC of the PASDAS was 0.67 (95% CI 0.55-0.79) and results for improvement and deterioration were 0.65 (95% CI 0.46-0.83) and 0.71 (95% CI 0.49-0.93), respectively.

Study details: Findings are from a retrospective cohort study that evaluated routine practice data of 408 patients with PsA.

Disclosures: This work was supported by the Regional Junior Researcher Grant from the Sint Maartenskliniek, Nijmegen, and the Radboudumc, Nijmegen, the Netherlands. The authors declared no conflicts of interest.

Source: Mulder MLM et al. Rheumatology (Oxford). 2022 (Jan 13). Doi: 10.1093/rheumatology/keac025.

Recommended Reading

How to make the most of your time with psoriasis patients
MDedge Rheumatology
Guselkumab controls axial involvement in PsA through 2 years
MDedge Rheumatology
Dietary recommendations for inflammatory rheumatic diseases
MDedge Rheumatology
Patients are interrupting DMARD use well into the COVID-19 pandemic
MDedge Rheumatology
PsA: Secukinumab provides early and clinically meaningful improvements in patient-reported outcomes
MDedge Rheumatology
Psoriasis with concomitant psoriatic arthritis tied to an increased risk for endometriosis
MDedge Rheumatology
Predicting the risk for uveitis in juveniles with PsA
MDedge Rheumatology
Comorbidities account for an increased risk for VTE in PsA
MDedge Rheumatology
PsA: Time to clinically meaningful response shorter with tofacitinib vs. placebo
MDedge Rheumatology
Doppler signals and bone erosions at enthesis indicate more severe PsA
MDedge Rheumatology